Press coverage about Dicerna Pharmaceuticals (NASDAQ:DRNA) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.7825589742926 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

Dicerna Pharmaceuticals (NASDAQ DRNA) traded down $0.42 during trading on Tuesday, reaching $7.18. 191,600 shares of the company’s stock were exchanged, compared to its average volume of 180,475. Dicerna Pharmaceuticals has a 1 year low of $2.42 and a 1 year high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. Dicerna Pharmaceuticals’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.68) earnings per share. equities analysts forecast that Dicerna Pharmaceuticals will post -3.04 EPS for the current year.

DRNA has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. ValuEngine raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $6.81.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with's FREE daily email newsletter.